Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunitybio Inc (IBRX)

Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,235,871
  • Shares Outstanding, K 984,965
  • Annual Sales, $ 14,750 K
  • Annual Income, $ -413,560 K
  • EBIT $ -261 M
  • EBITDA $ -222 M
  • 60-Month Beta 0.10
  • Price/Sales 138.94
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 89.71% (+10.22%)
  • Historical Volatility 74.75%
  • IV Percentile 5%
  • IV Rank 4.05%
  • IV High 409.22% on 01/27/25
  • IV Low 76.21% on 11/13/25
  • Expected Move (DTE 24) 0.31 (14.57%)
  • Put/Call Vol Ratio 0.35
  • Today's Volume 6,076
  • Volume Avg (30-Day) 4,009
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 261,110
  • Open Int (30-Day) 280,971
  • Expected Range 1.79 to 2.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.09
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +46.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +5.00%
on 12/19/25
2.50 -16.00%
on 12/12/25
+0.02 (+0.96%)
since 11/21/25
3-Month
1.95 +7.69%
on 11/14/25
2.75 -23.64%
on 10/03/25
-0.49 (-18.92%)
since 09/23/25
52-Week
1.83 +14.75%
on 05/07/25
4.27 -50.82%
on 02/19/25
-0.57 (-21.35%)
since 12/23/24

Most Recent Stories

More News
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer

Results from the QUILT-3.032 study of 80 subjects, published in The Journal of Urology, showed 96% disease-specific survival and 83% progression-free survival at 36 months, demonstrating...

IBRX : 2.10 (-7.49%)
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, to receive a positive recommendation for marketing...

IBRX : 2.10 (-7.49%)
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

Insights show patients with non-muscle invasive bladder cancer want to explore new treatment options, yet fewer than one in five say their doctors discuss all available procedures/treatments at most or...

IBRX : 2.10 (-7.49%)
ImmunityBio: Q3 Earnings Snapshot

ImmunityBio: Q3 Earnings Snapshot

IBRX : 2.10 (-7.49%)
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

Q3 2025 Revenue and Other Income Growth with Continued Strong Sales Momentum: $33.7 million of total revenue and other income, up from $26.4 million in Q2 2025. ...

IBRX : 2.10 (-7.49%)
Biotech Breakouts: 3 Stocks With Massive Upside Potential

Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential

VKTX : 36.41 (+2.85%)
MAZE : 42.30 (+0.76%)
IBRX : 2.10 (-7.49%)
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals

/CNW/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August 2025[1] signaled the recent wave of regulatory...

ONCY : 0.9540 (-1.50%)
ANIX : 3.30 (-2.08%)
ICCM : 0.6600 (+0.72%)
REGN : 785.17 (+0.75%)
IBRX : 2.10 (-7.49%)
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals

Issued on behalf of Oncolytics Biotech Inc.

ONCY : 0.9540 (-1.50%)
ANIX : 3.30 (-2.08%)
ICCM : 0.6600 (+0.72%)
REGN : 785.17 (+0.75%)
IBRX : 2.10 (-7.49%)
ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

Severe lymphopenia, an adverse treatment effect associated with chemotherapy, radiotherapy, and immunotherapy, significantly lowers overall survival in non-small...

IBRX : 2.10 (-7.49%)
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone

/CNW/ -- Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with...

ONCY : 0.9540 (-1.50%)
AGEN : 3.31 (-5.70%)
CSTL : 40.20 (-2.88%)
STRO : 10.38 (+0.10%)
IBRX : 2.10 (-7.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

ImmunityBio Inc. is a late-clinical-stage immunotherapy company developing therapies which drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems. ImmunityBio Inc., formerly known as NantKwest...

See More

Key Turning Points

3rd Resistance Point 2.39
2nd Resistance Point 2.32
1st Resistance Point 2.21
Last Price 2.10
1st Support Level 2.03
2nd Support Level 1.96
3rd Support Level 1.85

See More

52-Week High 4.27
Fibonacci 61.8% 3.34
Fibonacci 50% 3.05
Fibonacci 38.2% 2.76
Last Price 2.10
52-Week Low 1.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar